Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide and, together with associated risk factors such as diabetes, hypertension, and dyslipidaemia, greatly impact patients’ quality of life and health care systems. This burden can be alleviated by fomenting lifestyle modifications and/or resorting to pharmacological approaches. However, due to several side effects, current therapies show low patient compliance, thus compromising their efficacy and enforcing the need to develop more amenable preventive/therapeutic strategies. In this scenario, medicinal and aromatic plants are a potential source of new effective agents. Specifically, plants from the Allioideae subfamily (formerly Alliaceae family), particularly those from the genus Allium and Tulbaghia, have been extensively used in traditional medicine for the management of several CVDs and associated risk factors, mainly due to the presence of sulphur-containing compounds. Bearing in mind this potential, the present review aims to gather information on traditional uses ascribed to these genera and provide an updated compilation of in vitro and in vivo studies validating these claims as well as clinical trials carried out in the context of CVDs. Furthermore, the effect of isolated sulphur-containing compounds is presented, and whenever possible, the relation between composition and activity and the mechanisms underlying the beneficial effects are pointed out.

Details

Title
Natural Products in Cardiovascular Diseases: The Potential of Plants from the Allioideae Subfamily (Ex-Alliaceae Family) and Their Sulphur-Containing Compounds
Author
Alves-Silva, Jorge M 1   VIAFID ORCID Logo  ; Zuzarte, Mónica 2   VIAFID ORCID Logo  ; Girão, Henrique 2   VIAFID ORCID Logo  ; Salgueiro, Lígia 3 

 Coimbra Institute for Clinical and Biomedical Research, University of Coimbra, 3000-548 Coimbra, Portugal; [email protected] (J.M.A.-S.); [email protected] (M.Z.); [email protected] (H.G.); Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3000-548 Coimbra, Portugal; Clinical Academic Centre of Coimbra, University of Coimbra, 3000-075 Coimbra, Portugal 
 Coimbra Institute for Clinical and Biomedical Research, University of Coimbra, 3000-548 Coimbra, Portugal; [email protected] (J.M.A.-S.); [email protected] (M.Z.); [email protected] (H.G.); Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3000-548 Coimbra, Portugal; Clinical Academic Centre of Coimbra, University of Coimbra, 3000-075 Coimbra, Portugal 
 Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; Chemical Process Engineering and Forest Products Research Centre, University of Coimbra, 3030-290 Coimbra, Portugal 
First page
1920
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22237747
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2700758506
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.